•
Oct 04, 2020

Revvity Q3 2020 Earnings Report

PerkinElmer reported revenue of $964.0 million with 36% reported growth and 34% organic growth. GAAP EPS from continuing operations was $1.57 and adjusted EPS was $2.09.

Key Takeaways

PerkinElmer reported strong financial results for the third quarter of 2020, with significant revenue growth driven by the Diagnostics segment. The company's GAAP EPS and adjusted EPS also showed substantial increases compared to the same period last year, reflecting improved profitability.

Revenue reached $964.0 million, demonstrating 36% reported growth and 34% organic growth.

GAAP EPS from continuing operations was $1.57, up from $0.53 in Q3 2019.

Adjusted EPS was $2.09, compared to $1.06 in Q3 2019.

Operating income from continuing operations was $248.0 million, significantly higher than $78.7 million in the prior year.

Total Revenue
$964M
Previous year: $707M
+36.4%
EPS
$2.09
Previous year: $1.06
+97.2%
Organic Revenue Growth
34%
Gross Profit
$527M
Previous year: $342M
+54.1%
Cash and Equivalents
$258M
Previous year: $393M
-34.3%
Free Cash Flow
$191M
Previous year: $90.1M
+112.2%
Total Assets
$6.87B
Previous year: $6.49B
+5.8%

Revvity

Revvity

Revvity Revenue by Segment

Forward Guidance

The Company forecasts for the fourth quarter of 2020, GAAP revenue in the range of $1.12 billion to $1.23 billion, GAAP earnings per share from continuing operations of $2.27 to $2.67 and, on a non-GAAP basis, adjusted earnings per share of $2.60 to $3.00.

Revenue & Expenses

Visualization of income flow from segment revenue to net income